These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29752179)

  • 1. The effect of eicosapentaenoic and docosahexaenoic acids on physical function, exercise, and joint replacement in patients with coronary artery disease: A secondary analysis of a randomized clinical trial.
    Alfaddagh A; Elajami TK; Saleh M; Elajami M; Bistrian BR; Welty FK
    J Clin Lipidol; 2018; 12(4):937-947.e2. PubMed ID: 29752179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.
    Elajami TK; Alfaddagh A; Lakshminarayan D; Soliman M; Chandnani M; Welty FK
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28710178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
    Nakao K; Noguchi T; Asaumi Y; Morita Y; Kanaya T; Fujino M; Hosoda H; Yoneda S; Kawakami S; Nagai T; Nishihira K; Nakashima T; Kumasaka R; Arakawa T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Yamamoto H; Hamasaki T; Yasuda S
    Trials; 2018 Jan; 19(1):12. PubMed ID: 29310688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial.
    Hariri E; Asbeutah AA; Malik A; Amangurbanova M; Chedid G; Daher R; Al Hammoud M; Welty FK
    Atherosclerosis; 2023 Dec; 387():117388. PubMed ID: 38056242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.
    Schwellenbach LJ; Olson KL; McConnell KJ; Stolcpart RS; Nash JD; Merenich JA;
    J Am Coll Nutr; 2006 Dec; 25(6):480-5. PubMed ID: 17229894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment.
    Alfaddagh A; Elajami TK; Saleh M; Mohebali D; Bistrian BR; Welty FK
    Atherosclerosis; 2019 Jun; 285():153-162. PubMed ID: 31055222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid.
    Allaire J; Harris WS; Vors C; Charest A; Marin J; Jackson KH; Tchernof A; Couture P; Lamarche B
    Prostaglandins Leukot Essent Fatty Acids; 2017 May; 120():8-14. PubMed ID: 28515020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial.
    Asbeutah AA; Daher R; Malik A; Hariri E; Alfaddagh A; Elajami TK; Welty FK
    Am J Cardiol; 2024 Aug; 225():98-104. PubMed ID: 38885922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study.
    Allaire J; Couture P; Leclerc M; Charest A; Marin J; Lépine MC; Talbot D; Tchernof A; Lamarche B
    Am J Clin Nutr; 2016 Aug; 104(2):280-7. PubMed ID: 27281302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ω-3 Ethyl ester results in better cognitive function at 12 and 30 months than control in cognitively healthy subjects with coronary artery disease: a secondary analysis of a randomized clinical trial.
    Malik A; Ramadan A; Vemuri B; Siddiq W; Amangurbanova M; Ali A; Welty FK
    Am J Clin Nutr; 2021 May; 113(5):1168-1176. PubMed ID: 33675344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Eicosapentaenoic Acid/Docosahexaenoic Acid on Coronary High-Intensity Plaques Detected Using Noncontrast T1-weighted Imaging: The AQUAMARINE EPA/DHA Randomized Study.
    Nakao K; Noguchi T; Miura H; Asaumi Y; Morita Y; Takeuchi S; Matama H; Sawada K; Doi T; Hosoda H; Nakashima T; Honda S; Fujino M; Yoneda S; Kawakami S; Nagai T; Nishihira K; Kanaya T; Otsuka F; Nakanishi M; Kataoka Y; Tahara Y; Goto Y; Kusano K; Yamamoto H; Omae K; Ogawa H; Yasuda S
    J Atheroscler Thromb; 2024 Feb; 31(2):122-134. PubMed ID: 37704431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
    Alfaddagh A; Elajami TK; Ashfaque H; Saleh M; Bistrian BR; Welty FK
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29246960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eicosapentaenoic Acid for Cardiovascular Events Reduction- Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Yokoyama Y; Kuno T; Morita SX; Slipczuk L; Takagi H; Briasoulis A; Latib A; Bangalore S; Heffron SP
    J Cardiol; 2022 Nov; 80(5):416-422. PubMed ID: 35914996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid?
    Iwamatsu K; Abe S; Nishida H; Kageyama M; Nasuno T; Sakuma M; Toyoda S; Inoue T
    Hypertens Res; 2016 Apr; 39(4):272-5. PubMed ID: 26739870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial.
    Myhre PL; Kalstad AA; Tveit SH; Laake K; Schmidt EB; Smith P; Nilsen DWT; Tveit A; Solheim S; Arnesen H; Seljeflot I
    J Intern Med; 2022 May; 291(5):637-647. PubMed ID: 34982486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
    Abdelhamid AS; Brown TJ; Brainard JS; Biswas P; Thorpe GC; Moore HJ; Deane KH; Summerbell CD; Worthington HV; Song F; Hooper L
    Cochrane Database Syst Rev; 2020 Feb; 3(3):CD003177. PubMed ID: 32114706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. n-3 fatty acids and cardiovascular events after myocardial infarction.
    Kromhout D; Giltay EJ; Geleijnse JM;
    N Engl J Med; 2010 Nov; 363(21):2015-26. PubMed ID: 20929341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial.
    Tsuchiya Y; Yanagimoto K; Nakazato K; Hayamizu K; Ochi E
    Eur J Appl Physiol; 2016 Jun; 116(6):1179-88. PubMed ID: 27085996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials.
    Martins JG
    J Am Coll Nutr; 2009 Oct; 28(5):525-42. PubMed ID: 20439549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
    Yurko-Mauro K; Kralovec J; Bailey-Hall E; Smeberg V; Stark JG; Salem N
    Lipids Health Dis; 2015 Sep; 14():99. PubMed ID: 26328782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.